Skip to content

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Precision oncology in advanced melanoma: molecular landscapes and personalized therapy recommendations from the Molecular Tumor Board Freiburg

Immune checkpoint inhibitors (ICIs) and BRAF/MEK kinase inhibitors have substantially improved survival in advanced melanoma; however, therapeutic resistance and severe toxicities underscore the ongoing need for alternative strategies. Here, we evaluate the clinical utility of multi-omic profiling, biomarker-stratified...

T. Lowinus, V. Schipperges, P. Metzger et al. · 0 citations
Open access Nov 2026

Cellular and spatial continuum of TAM functional states governs immune exclusion and dictates immune checkpoint resistance in melanoma

Immune checkpoint inhibitor (ICI) therapy has transformed melanoma treatment, yet many patients either fail to respond or develop resistance after an initial response. The cellular and spatial determinants within the tumor microenvironment (TME) that underlie these divergent ICI therapy outcomes remain poorly defined....

Sajib Chakraborty, Eyleen Corrales, Ira Godbole et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.